Background: Aortic stenosis is the most common cause of valvular heart disease with no means of prevention. Lowering serum levels of calcium or phosphate are potential preventive strategies but observational studies on the associations with aortic stenosis are inconsistent. Design and methods: A case-control study was conducted in 132 individuals undergoing echocardiography (63 with aortic stenosis and 69 without) and the results combined with three other comparable studies (914 individuals overall) to provide a summary odds ratio of aortic stenosis for a 0.1 mmol/L increase (approximately one standard deviation) in calcium and phosphate respectively. The relationship between calcium and phosphate and the severity of aortic stenosis, according to peak trans-aortic velocity, was also examined in the case-control study using linear regression. Results: Both calcium and phosphate were positively associated with aortic stenosis. The summary odds ratio for a 0.1 mmol/L increase in calcium was 1.79 (95% confidence interval 1.07-2.99), p ¼ 0.027 and for phosphate it was 1.47 (1.08-2.01), p ¼ 0.015. Peak trans-aortic velocity increased with phosphate levels, 9% (4%-14%) per 0.1 mmol/L, p ¼ 0.001, but not with calcium, p ¼ 0.089. Conclusions: If the associations are causal and reversible, these results indicate that a small reduction in calcium or phosphate levels, within the physiological rage, would translate into a clinically significant reduction in the risk of aortic stenosis. Randomised trials of calcium and phosphate lowering therapies in aortic stenosis are needed.
Introduction
Aortic stenosis is the most common cause of death from valvular heart disease. 1 It is caused by calcium phosphate crystal deposition on the aortic valve, 2 leading to progressive obstruction of blood flow from the heart and death in symptomatic cases, unless the valve is surgically replaced. 3 There is no known means of prevention.
A possible preventive strategy is to reduce the blood level of calcium or phosphate, as this may reduce calcium phosphate deposition on the valve. There is, however, uncertainty over the relationship between serum calcium and serum phosphate and the prevalence of aortic stenosis in observational studies; some concluding a positive association with serum phosphate but not calcium, 4, 5 others a positive association with serum calcium but not phosphate 6, 7 and others concluding no association with either. 8, 9 To help clarify the position we carried out a new case-control study on the associations of serum calcium and serum phosphate with aortic stenosis and combined the results with those of other observational studies to make an overall assessment of the evidence. We sought to estimate the change in risk of aortic stenosis for a unit change in serum calcium or serum phosphate and to quantify the potential for prevention.
Methods
In our case-control study, 63 consecutive patients with echocardiographically confirmed aortic stenosis were identified, between July 2016 and January 2017, from cardiology clinics and wards at Barts Heart Centre, London. Aortic stenosis was defined as thickened aortic valve leaflets with a peak trans-aortic velocity (Vmax) greater than or equal to 2m/s. Previous studies have defined aortic stenosis using Vmax cut-offs ranging between about 2.0 m/s and 2.5 m/s. [10] [11] [12] We adopted the lower level of > 2.0 m/s to be inclusive. In this study we excluded patients with bicuspid aortic valve (five) or rheumatic valve disease (four). A further 69 patients, without aortic stenosis, who were undergoing echocardiography for other reasons, were invited to participate in the study as controls. Patients gave written consent to participate and the study was approved by the North West-Preston Research Ethics Committee, part of the National System.
Peripheral blood samples were collected from each subject and assayed for serum phosphate concentrations using the colorimetric reaction method with ammonium molybdate, 13 and for total calcium, using indirect potentiometry.
14 Biochemical analyses were performed 'blind', that is, without knowledge of which samples were cases or controls.
The statistical analyses were carried out on all 132 subjects. The clinical and echocardiographic characteristics of the cases and controls were compared using Fisher's exact test for categorical variables, and unpaired t-tests (where data were Gaussian) or Wilcoxon Rank Sum tests (where data were nonGaussian) for continuous variables. Unadjusted odds ratios and odds ratios adjusted for potential confounding factors were calculated using logistic regression, for tertiles of serum calcium and serum phosphate (tertiles based on control group data), and for a 0.1 mmol/L increase. The association between serum calcium or phosphate and the severity of aortic stenosis was examined by performing linear regressions of serum calcium and phosphate with the Vmax recorded on echocardiography.
We compared our results with those of other epidemiological studies of serum phosphate or calcium and aortic stenosis, identifying studies using a Medline search (1950 to 2016), using search terms of 'calcium', 'phosphate' and 'aortic stenosis', in any language, limited to human subjects. We identified 711 articles, which reduced to 100 after screening the title, to 25 after inspection of the abstracts and to four (including the present one) after examining the full articles. Study data were abstracted separately by two investigators and any differences resolved by discussion.
We combined estimates of the average increase in risk of aortic stenosis, expressed as the odds ratio for a 0.1 mmol/L increase in serum calcium or serum phosphate from the different studies using a random effects model. 15 Where odds ratios were not reported they were estimated from the means and standard deviations of serum calcium and serum phosphate in cases and controls. This was done for each study by simulating 10,000 datasets of the same size, with levels of serum calcium and serum phosphate simulated using the reported means and standard deviations assuming the distributions were Gaussian (which was the case in our case-control study). For each simulated dataset logistic regression was used to calculate the odds ratio for a 0.1 mmol/L increase in serum calcium and serum phosphate and the associated standard errors. The medians of the 10,000 odds ratios and standard errors were then used in the estimation of the combined odds ratio. Statistical significance was taken as p < 0.05. Stata version 14 was used for all analyses. Table 1 shows the clinical characteristics of the 63 individuals with aortic stenosis and the 69 controls without. There were no statistically significant differences between the groups apart from the expected differences in echocardiographic parameters reflecting the presence or absence of aortic stenosis in cases and controls respectively.
Results
The concentrations of serum calcium (with 95% confidence intervals), in cases and controls respectively, were 2.37 mmol/L (2.34-2.39) and 2.34 mmol/L (2.32-2.37) ( p ¼ 0.154 for difference) and for serum phosphate, the concentrations were 1.13 mmol/L (1.09-1.17) and 1.05 mmol/L (1.01-1.10) respectively ( p ¼ 0.011 for difference). Table 2 gives the odds ratios of aortic stenosis according to tertile groups of serum calcium and serum phosphate, and for a 0.1 mmol/L increase, with and without adjustment for related factors. After adjustment for age there was no statistically significant increase in the risk of aortic stenosis among patients in the third tertile of serum calcium compared with the first tertile (odds ratio 1.66, (0.71-3.91), p ¼ 0.25), nor was there an increase in risk for a 0.1 mmol/L increase (odds ratio 1.26 (0.86-1.84), p ¼ 0.24). After adjustment for age and vitamin D supplement use, among patients in the third tertile group of serum phosphate the risk of aortic stenosis was 3.4 times that in the first tertile group (odds ratio 3.40 (1.32-8.76), p ¼ 0.01) and the risk increased by 40% for a 0.1 mmol/L increase (odds ratio 1.40 (1.11-1.75), p ¼ 0.004). Figure 1 shows that serum levels of phosphate correlated positively with the Vmax; an estimated 9% (4-14%) increase in Vmax per 0.1 mmol/L increase in serum phosphate, or an 8% (13-3%) decrease in Vmax per 0.1 mmol/L decrease in serum phosphate (Figure 1 , lower plot), p ¼ 0.001. There was no statistically significant association between serum calcium and Vmax ( Figure 1, upper plot) ; p ¼ 0.089. Table 3 gives details of the four observational studies, 4, 5, 7 including the present one, examining the associations between serum calcium, serum phosphate and aortic stenosis. One study gave results for serum calcium but not for serum phosphate.
7 Figure 2 shows a forest plot for these four studies (218 cases and 696 controls) giving odds ratios for a 0.1 mmol/L increase in serum calcium (upper part) and serum phosphate (lower part). The summary estimates indicate a statistically significant increased risk of aortic stenosis for serum calcium (odds ratio 1.79 (1.07-2.99), p ¼ 0.027) and for serum phosphate (odds ratio 1.47 (1.08-2.01), p ¼ 0.015). Tests for heterogeneity yielded I 2 ¼ 89.6% and I 2 ¼ 88.4% respectively ( p < 0.001 for both).
Discussion
The results of our case-control study show a statistically significant increased risk of aortic stenosis with increasing serum phosphate concentrations, but not for serum calcium. However, when our results are combined with those of comparable studies published to date, the totality of evidence shows statistically significant associations for both serum calcium and serum phosphate; an increased risk of aortic stenosis of 79% per 0.1 mmol/L increase in serum calcium and of 47% per 0.1 mmol/L increase in serum phosphate. Aortic stenosis is the most common heart valve disorder, affecting about 12% of people over the age of 75 years based on meta-analyses of population studies. 16, 17 In England and Wales the number of recorded deaths has approximately doubled in the last decade, an increase that exceeds that expected from an aging population. 6 There has been a consequent increase in the number aortic valve replacements, which is now the most commonly performed valve surgery in developed countries; 67,500 were carried out in North America in 2012.
18 Surgery carries about a 1-2% risk of death, 19 about a 10% risk of stroke or re-operation, 20 and a need for cardiac rehabilitation. 21, 22 Aortic stenosis is an overlooked public health problem with a pressing need for a preventive solution.
Calcium lowering drugs, such as bisphosphonates, are widely used in medicine for the treatment of hypercalcaemia in malignancy. Such drugs could be repurposed for use in the prevention of aortic stenosis, but there is uncertainty over whether the reduction in serum calcium levels would be sustained, because of the negative feedback loop which increases parathyroid hormone secretion to restore calcium levels. The SALTIRE 2 trial is currently examining whether alendronate (or denosumab) slows or arrests the progression of aortic stenosis. 23 Phosphate lowering drugs, which bind dietary phosphate, are also widely used in medicine, to prevent bone disease, in patients on renal dialysis, whose serum phosphate levels are high because of a failure of renal excretion. Such drugs could be repurposed for use in aortic stenosis, if it could be shown that the therapeutic effect is not countered by renal retention of phosphate, in patients with preserved renal function. The Prevention of Aortic Stenosis Pilot trial is currently examining the efficacy of sevelamer in patients with aortic stenosis. 24 The study presented here, and those included in the meta-analysis, are non-randomised and therefore do not establish a causal association. In our case-control study, we adjusted for potential risk factors, including a history of coronary artery disease, renal failure and medication use that may influence serum calcium or phosphate levels, but residual confounding is possible. The heterogeneity observed between studies in the meta-analysis was due to inclusion of unadjusted data from one study, 4 which may have overestimated the effect. There was no heterogeneity after excluding this study and the overall summary estimates remained statistically significant; odds ratios were 1.31 (1.11-1.55) and 1.26 (1.10-1.44) per 0.1 mmol/L increase in serum calcium and serum phosphate respectively. We found that the severity of aortic stenosis increased with serum phosphate concentrations (9% increase in Vmax per 0.1 mmol/L increase in serum phosphate) but not with serum calcium. Whilst this result is consistent with one other study, 25 a difference in effect between calcium and phosphate would be surprising, given that the mineral that deposits on the aortic valve is calcium phosphate in equal ionic concentrations. The finding, therefore, needs confirmation and this work may provide a stimulus for other groups to conduct similar studies, or examine existing data on stored samples, to examine the associations between serum calcium, phosphate and aortic stenosis.
The mechanism responsible for calcium phosphate deposition on an aortic valve leading to aortic stenosis is unknown. Some regard it as a physico-chemical process that depends on the blood concentrations of calcium or phosphate, in a state of dynamic equilibrium, 26 whilst others regard it is an active inflammatory process similar to atherosclerosis, [27] [28] [29] although randomised trials of proven therapies for coronary artery disease have shown no benefit in aortic valve disease. [30] [31] [32] Whatever the mechanism, the positive associations demonstrated here strengthen the case for examining, in randomised trials, whether serum calcium or serum phosphate or both can be safely lowered in patients with aortic stenosis and, if so, whether this will improve clinical outcomes.
More than 100,000 people die from or require surgery for aortic stenosis each year in the UK and USA. 1, 16 The lack of an effective treatment to slow or arrest the progression of aortic stenosis is a significant gap in preventive practice. The positive associations between serum calcium, serum phosphate and aortic stenosis shown in the present study are plausible given the known composition of crystals that cause the stenosis, and may be modifiable using licensed drugs repurposed for the prevention of aortic stenosis. Small reductions in serum calcium or serum phosphate have the potential to significantly reduce the risk of aortic stenosis.
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